New Zealand National Health Products Bill Regulatory Assessment

The problem

Small natural health companies in New Zealand were concerned that a new Natural Health and Supplementary Products Bill would reduce consumer choice, increase prices, and potentially put them out of business due to the cost associated with the new regulation.

How we helped

Castalia undertook a cost-benefit analysis to identify whether the regulatory regime was economically justified. Our conclusion was that some elements were justified, however we found that the regime did not meet the criteria for risk-proportionate and growth-focused regulation. We identified possible alternative that were low-cost and would meet these criteria.


Our client, a participant in the natural health products sector, used the report to present their case to the New Zealand government. The Natural Health and Supplementary Products Bill was not reinstated after it lapsed, and so did not become law.

Our team

No posts found.

How can we help you?

How can we help you?